331 related articles for article (PubMed ID: 4068189)
1. Consensus conference. Adjuvant chemotherapy for breast cancer.
JAMA; 1985 Dec; 254(24):3461-3. PubMed ID: 4068189
[TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
4. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
[TBL] [Abstract][Full Text] [Related]
5. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
6. Significance of axillary lymph node metastasis in primary breast cancer.
Jatoi I; Hilsenbeck SG; Clark GM; Osborne CK
J Clin Oncol; 1999 Aug; 17(8):2334-40. PubMed ID: 10561295
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
10. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
12. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
13. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
[TBL] [Abstract][Full Text] [Related]
15. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
16. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
17. Prognosis of node-positive breast cancer patients who underwent parasternal lymph node biopsy during surgery followed by doxorubicin- or mitoxantrone-containing adjuvant chemotherapy.
Kanno M; Nakamura S; Uotani C; Yamanaka S; Terasaki Y; Tsugawa K; Noguchi M
J Chemother; 2000 Oct; 12(5):435-41. PubMed ID: 11128565
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant chemotherapy in breast cancer: present status].
Maass H; Kaufmann M; Eidtmann H; Jonat W; Kubli F
Geburtshilfe Frauenheilkd; 1984 Nov; 44(11):703-9. PubMed ID: 6392005
[TBL] [Abstract][Full Text] [Related]
19. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
20. The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study.
Montero AJ; Rouzier R; Lluch A; Theriault RL; Buzdar AU; Delaloge S; Bermejo B; Le M; Kau SW; Dunant A; Arriagada R; Spielmann M; Garcia-Conde J; Sahin AA; Singletary SE; Hortobagyi GN; Valero V
Cancer; 2005 Jul; 104(2):229-35. PubMed ID: 15937910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
